Physician profile
Phyllis NP Woo
NPI 1184931263
$808.39
in general payments reported to CMS, 2019-2025
10 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $193 · 2023: $67.57 · 2024: $286 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600 · Travel and Lodging: $15.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.16 |
| Travel and Lodging | $15.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $291.67 | 2022-2025 | Arexvy, Rotarix, Pediarix |
| Lilly USA, LLC | $194.14 | 2022-2024 | Mounjaro |
| Novo Nordisk INC | $91.46 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $55.82 | 2024-2025 | |
| Viiv Healthcare Company | $45.54 | 2024 | Apretude |
| Sanofi Pasteur INC. | $35.84 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $27.19 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $27.19 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $22.08 | 2025 | Slynd |
| Agios Pharmaceuticals, INC. | $17.46 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.